Common Contracts
2 similar Preferred Stock Purchase Agreement contracts by Capstone Therapeutics Corp.
SERIES B-2 PREFERRED STOCK PURCHASE AGREEMENTPreferred Stock Purchase Agreement • August 14th, 2017 • Capstone Therapeutics Corp. • Pharmaceutical preparations • Delaware
This Series B-2 Preferred Stock Purchase Agreement (this “Agreement”) is made and entered into as of August 11, 2017, by and among LipimetiX Development, Inc., a Delaware corporation (the “Company”), and Capstone Therapeutics Corp., a Delaware corporation (the “Purchaser”).
SERIES B-2 PREFERRED STOCK PURCHASE AGREEMENTPreferred Stock Purchase Agreement • August 11th, 2017 • Delaware
The Company previously sold to investors 94,537 shares of the Company’s Series B-1 Preferred, par value $0.00001 per share (the “Series B-1 Preferred Stock”).
